Premium
Overexpression of Rab3C, a secretory Rab GTPase, as a predictive marker of survival outcome and adjuvant chemotherapy response for colorectal cancer patients (59.5)
Author(s) -
Su Chia Yi,
Lim Christina,
Jan Yi hua,
Chang Yu Chan,
Chen Chi Long,
Hsiao Michael
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.59.5
Subject(s) - rab , colorectal cancer , tissue microarray , medicine , chemotherapy , cancer , stage (stratigraphy) , predictive marker , immunohistochemistry , oncology , metastasis , carcinogenesis , cancer research , pathology , gtpase , biology , paleontology , biochemistry
Rab GTPases, a large family of Ras small GTPase, are critical in regulating membrane traffic and cell motility. Rabs has recently been demonstrated to play an important role in carcinogenesis. However, the function role of Rab3C, one of the secretory Rabs, in cancer has not yet been elucidated. To investigate the clinicopathological function of Rab3C, immunohistochemical staining of Rab3C was performed on tissue microarray specimens of 215 colorectal adenocarcinoma. Rab3C immunoexpression was significantly higher in tumors compared to the corresponding normal tissue and high Rab3C expression was correlated with distant metastasis, higher pathological stage, and tumor recurrence. High Rab3C was associated with poor prognosis in either early stage or late stage colon cancer patients. In multivariate analyses, high Rab3C expression retained its independently prognostic significance for both overall survival (P = 0.001) and disease‐free survival (P < 0.001). Further experimental results showed that Rab3C overexpression promoted tumor progression in vitro and vivo. More importantly, our data also showed that stage II and III patients with high Rab3C expression tumors benefit from adjuvant chemotherapy while patients with low Rab3C expression tumors had no benefit from adjuvant chemotherapy. In conclusion, we demonstrated that Rab3C expression, as a predictive marker for prognosis and therapeutic outcome, is critical for cancer progression.